Clinical trials: Androgen Deprivation Therapy
Cancer of Prostate
De-implementation of Low Value Castration for Men With Prostate Cancer
This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen…
- Trial name
- DeADT (NCT03579680)
- Testing
- ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Prostate Cancer
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer by lowering the amount of androgens the body…
- Trial name
- NCT00288080
- Testing
- Dexamethasone, Prednisone, docetaxel
- Where
- 254 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Radiation Therapy Oncology Group
High Risk Prostate Carcinoma
Towards Optimal Treatment for High Risk Prostate Cancer
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
- Trial name
- HYPOPRIME (NCT06204341)
- Testing
- HYPOPRIME treatment
- Where
- Netherlands
- Volunteers
- 207 people
- Sponsor
- Haaglanden Medical Centre
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC.
- Trial name
- NCT04191096
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 234 sites in United States, Australia and 27 more
- Volunteers
- 1,251 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
- Trial name
- NCT01215513
- Testing
- Degarelix
- Where
- 11 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Risk of Bone Fracture Occurrences
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
- Trial name
- TREAT2 (NCT01214291)
- Testing
- Toremifene
- Where
- United States
- Sponsor
- GTx
Vasomotor Symptoms, Prostate Cancer
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
- Trial name
- NCT07568236
- Testing
- Fezolinetant
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients
The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients.
- Trial name
- NCT05202340
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
- Trial name
- IAS (NCT00223665)
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Washington
Prostate Cancer
An Alternative to A Fixed Schedule In Management Of Prostate Cancer
The male sex-hormone called testosterone is known to play a key role in the growth of prostate cancer. The usual treatment for the disease involves suppression of hormones (testosterone) by anti-hormonal treatment for an unknown…
- Trial name
- TADS (NCT01056562)
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Prostate Cancer (PCa) in ADT, Rehabilitation
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility. The main aim of the current study is to assess feasibility of a tailored exercise program as measured by adherence…
- Trial name
- ReCaP (NCT06238596)
- Testing
- rehabilitation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00016913
- Testing
- carboplatin, estramustine, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Sarcopenia, Prostate Cancer
Identifying Fundamental Mechanisms of Skeletal Muscle Ageing in Older Men Undergoing Androgen Deprivation Therapy: a Feasibility Study
To find out whether it is possible to run a study looking at the underlying markers of ageing in muscle quality and quantity in men receiving Androgen Deprivation Therapy for prostate cancer treatment.
- Conditions
- Sarcopenia, Prostate Cancer, Muscle Atrophy, Androgen Deprivation Therapy
- Trial name
- MASS-ADT (NCT07134439)
- Volunteers
- 20 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Prostatic Neoplasms, Exercise Therapy
Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy
Exercise intervention for men with prostate cancer on androgen deprivation therapy.
- Conditions
- Prostatic Neoplasms, Exercise Therapy, Androgen Deprivation Therapy
- Trial name
- NCT02631681
- Testing
- Group based exercise
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Herlev Hospital
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castrate-sensitive Prostate Cancer
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level…
- Trial name
- LIBERTAS (NCT05884398)
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 420 people
- Sponsor
- Janssen Research & Development, LLC
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06305598
- Testing
- Biopsy, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute